News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Cambridge-Based Biotech Rodin Therapeutics Snags $12.9 Million Series A Financing

5/29/2014 7:40:29 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Rodin Secures $12.9M Series A Financing to Develop Novel Treatments for CNS Disorders

Cambridge, MA - May 29, 2014 - Rodin Therapeutics, Inc., a biotechnology company applying insights of epigenetics to novel therapeutics for neurological disorders, has closed a $12.9M Series A financing round. Current investors Atlas Venture and Johnson & Johnson Development Corporation (JJDC) led the financing round. Rodin will use the new funds to advance its pipeline of selective epigenetic modulators towards the clinic.

"Rodin has spent the last year validating the thesis that an unique chemistry approach, high potential biology, and a strong team could drive generation of compelling therapies for CNS diseases," said Bruce Booth, Rodin's Chairman and acting CEO, and a Partner at Atlas Venture. "The Series A investment is a culmination of our efforts over the last 12 months to start a preeminent company in the field."

The Rodin approach is the product of a strategic partnership with Proteros, a founding shareholder in Rodin. Proteros' capabilities in structure-accelerated lead discovery enables an orthogonal evaluation of the interactions of small molecules as they bind to key epigenetic targets.

Since its inception in March 2013, Rodin has advanced its internal pipeline of epigenetic modulators and obtained an exclusive license to an additional chemical series developed at the Broad Institute and tested at Rodin.

The company has also assembled an esteemed Scientific Advisory Board, chaired by Li-Huei Tsai, Professor at the Massachusetts Institute of Technology.

"Epigenetic modulators have the potential to be a powerful addition to the therapies we have to treat Alzheimer's disease and other disorders of cognition" said Dr. Tsai. "I am delighted to be working with Rodin on the advancement of these therapies."

Additional members of the SAB include Jeffrey Nye of Johnson & Johnson Innovation, Marcelo Wood from the University of California, Irvine, Lisa Monteggia from the University of Texas Southwestern, Andre Fischer from the University of Gottingen, Ed Holson of the Broad Institute, and Stephen Haggarty from the Massachusetts General Hospital.

About Rodin Therapeutics

Rodin Therapeutics is discovering and developing first in class therapeutics for cognitive disorders, applying unique insights into the role of epigenetics and best in class structural biology capabilities. Applying Rodin's unique access to the Proteros structural biology platform and deep experience in CNS drug development, the company has identified high potential targets and novel chemical strategies to address high unmet clinical needs. Rodin was co-founded by Atlas Venture and Proteros Biostructures, with financing from the Johnson & Johnson Development Corporation (JJDC).

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus